Plain-English translation of NCT04158635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether —a medication that may help blood flow through tumors—works better when combined with two standard chemotherapy drugs ( and ) for people with unresectable pancreatic cancer. Researchers want to see if this three-drug combination is safe and whether it helps shrink tumors better than chemotherapy alone.
Pancreatic cancer that cannot be surgically removed is very difficult to treat, and current chemotherapy has limited effectiveness. This medication may work by changing how blood flows through the tumor, potentially making it easier for chemotherapy to reach and destroy cancer cells.
You would receive the three-drug combination in 21- or 28-day cycles. Two of the chemotherapy drugs are given by IV infusion over 30 minutes on days 1, 8, and 15 of each cycle, while the new medication is taken by mouth twice daily for varying durations depending on which group you are assigned to. You would continue treatment as long as your cancer does not progress and you tolerate the medication well. After treatment ends, you would have follow-up appointments at 30 days and then every 2 months or as needed to monitor your health.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States